. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: J Infect. 2019 Apr 6;78(6):476–483. doi: 10.1016/j.jinf.2019.04.007

Table 1.

SV40 neutralizing antibody positivity among Colombian and Nicaraguan subject groups

Country	Group^a	Group criteria	Total subjects	No. SV40 antibody positive (%)^b	SV40 neutralizing antibody titers (median)
Colombia	A	Cervical cancer patients	70	12 (17.1)	1:20–1:200 (1:20)
	B	Matched cancer controls	70	7 (10.0)	1:20–1:1000 (1:80)
	C	General population	320	77 (24.1)	1:10–1:1000 (1:20)
	D	Sex workers	57	22 (38.6)	1:10–1:100 (1:40)
		Total (Groups A-D):	517	118 (22.8)	1:10–1:1000 (1:20)
Nicaragua	E	Endoscopy patients	149	19 (12.8)	1:10–1:200 (1:20)

Sample collection dates: Groups A–C, 1968; Group D, 1970; Group E, 2010.

Statistical significance: Group C vs. Groups A+B, p = 0.0131; Group D vs. Group C, p = 0.0185; Groups A–D (Total) vs. Group E, p = 0.0143; Group C vs. Group E, p = 0.0099; Group C-(vbc) vs. Groups A+B, p = 0.0039. (vbc) = Birth cohort that contains potential vaccinees (birth dates 1949–1960).